全文获取类型
收费全文 | 1072382篇 |
免费 | 73406篇 |
国内免费 | 1367篇 |
专业分类
耳鼻咽喉 | 15013篇 |
儿科学 | 34666篇 |
妇产科学 | 28658篇 |
基础医学 | 153223篇 |
口腔科学 | 29591篇 |
临床医学 | 94610篇 |
内科学 | 203424篇 |
皮肤病学 | 24521篇 |
神经病学 | 81374篇 |
特种医学 | 43035篇 |
外国民族医学 | 201篇 |
外科学 | 163048篇 |
综合类 | 21693篇 |
现状与发展 | 1篇 |
一般理论 | 268篇 |
预防医学 | 74439篇 |
眼科学 | 24430篇 |
药学 | 86207篇 |
7篇 | |
中国医学 | 2767篇 |
肿瘤学 | 65979篇 |
出版年
2019年 | 7786篇 |
2018年 | 11325篇 |
2017年 | 8928篇 |
2016年 | 10131篇 |
2015年 | 11298篇 |
2014年 | 15319篇 |
2013年 | 22271篇 |
2012年 | 30688篇 |
2011年 | 32404篇 |
2010年 | 19016篇 |
2009年 | 17897篇 |
2008年 | 30076篇 |
2007年 | 32202篇 |
2006年 | 32803篇 |
2005年 | 31159篇 |
2004年 | 29867篇 |
2003年 | 28682篇 |
2002年 | 27641篇 |
2001年 | 60136篇 |
2000年 | 61584篇 |
1999年 | 51019篇 |
1998年 | 12489篇 |
1997年 | 11018篇 |
1996年 | 10360篇 |
1995年 | 10314篇 |
1994年 | 9340篇 |
1993年 | 8840篇 |
1992年 | 37850篇 |
1991年 | 36338篇 |
1990年 | 35790篇 |
1989年 | 34349篇 |
1988年 | 30901篇 |
1987年 | 30031篇 |
1986年 | 28261篇 |
1985年 | 26487篇 |
1984年 | 19200篇 |
1983年 | 16115篇 |
1982年 | 8817篇 |
1979年 | 17040篇 |
1978年 | 11412篇 |
1977年 | 10217篇 |
1976年 | 8844篇 |
1975年 | 10067篇 |
1974年 | 11655篇 |
1973年 | 11272篇 |
1972年 | 10766篇 |
1971年 | 10104篇 |
1970年 | 9261篇 |
1969年 | 8938篇 |
1968年 | 7923篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
24.
25.
26.
27.
28.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
29.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
30.
Pradeep Balasubramanian M.D. C. R. Srinivas M.D. Pavai Arunachalam M.S. M.Ch. K. S. Thirumurthy M.S. M.Ch. P. R. Rajkumar M.S. M.Ch. H. Manuvidhya M.B.B.S. 《Pediatric dermatology》2015,32(3):e78-e81
We report on a child with several café au lait spots in association with a lumbar lipomeningomyelocele as an apparently new association. Cutaneous markers, the identification of which plays a crucial role in the early diagnosis and management of spinal malformations, can accompany occult spinal dysraphism. Herein we report a case of lumbar lipomeningomyelocele associated with an overlying café au lait spot that served as a marker of occult spinal dysraphism. The patient also had segmental café au lait spots on the face, making the association unique. 相似文献